REGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Regeneron Pharmaceuticals Inc (REGN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong long-term growth potential, driven by its robust pipeline, key upcoming catalysts, and expanding product portfolio. Despite some short-term challenges, the stock's fundamentals and analyst sentiment support a positive outlook.
The stock's technical indicators present a mixed picture. The MACD is negative and expanding, indicating bearish momentum, while the RSI is neutral at 42.361. However, the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting an upward trend in the long term. The current pre-market price of $770.4 is below the pivot level of $784.559, with support at $761.177. This suggests a potential buying opportunity near support levels.
Strong analyst sentiment with multiple price target increases, including Guggenheim's $975 target and JPMorgan's $950 target.
Key upcoming catalysts such as FDA decisions and data readouts for melanoma and other treatments.
Expanding product portfolio with approvals like Lynozyfic and Dupixent's new indications.
Hedge funds significantly increasing their positions, indicating institutional confidence.
Insider selling has increased by 145.23% over the last month, which may indicate caution among company executives.
Net income and EPS declined YoY in Q4 2025, reflecting short-term financial challenges.
Competitive pressures on key products like Eylea and Dupixent.
In Q4 2025, Regeneron's revenue increased by 2.51% YoY to $3.88 billion, and gross margin improved to 89.4%. However, net income dropped by 7.97% YoY to $844.6 million, and EPS declined by 2.97% YoY to $7.84. While revenue growth remains steady, profitability metrics indicate short-term challenges.
Analyst sentiment is highly positive, with multiple firms raising price targets and maintaining Buy or Outperform ratings. Guggenheim, JPMorgan, and Raymond James highlight strong pipeline potential and future growth opportunities, while Cantor Fitzgerald and Wells Fargo note undervaluation and upside potential despite limited short-term catalysts.
